- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- Not listed
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 580
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Edema
- Interventions
- Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
- Device · Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more
- Conditions
- Glaucoma
- Interventions
- Ranibizumab, Ranibizumab and MMC, MMC
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- AGN208397 intravitreal injection, dexamethasone intravitreal implant
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Congenital Diaphragmatic Hernia
- Interventions
- Fetal Endotracheal Occlusion (FETO)
- Device
- Lead sponsor
- Eyal Krispin
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Kidney Failure, Vascular Graft Occlusion
- Interventions
- PEG-hirudin
- Drug
- Lead sponsor
- Speedel Pharma Ltd.
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Ischemic Stroke
- Interventions
- MT+CAS with IV-AP, MT+CAS with PO-AP, MT+CAT with PO-AP
- Procedure
- Lead sponsor
- Mercy Health Ohio
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 60
- States / cities
- Mobile, Alabama • Glendale, California • Irvine, California + 54 more
- Conditions
- Graft Occlusion, Vascular, Coronary Restenosis, Atherosclerosis
- Interventions
- BO-653
- Drug
- Lead sponsor
- Chugai Pharma USA
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Burlingame, California + 24 more
- Conditions
- Large Vessel Occlusion, Acute Ischemic Stroke
- Interventions
- transcutaneous auricular vagal nerve stimulation, Sham transcutaneous vagal nerve stimulation
- Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Radial Artery Occlusion
- Interventions
- Allen's test, Distal pulses
- Other
- Lead sponsor
- Creighton University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska
- Conditions
- Congenital Diaphragmatic Hernia
- Interventions
- FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)
- Device
- Lead sponsor
- Dr Erin Perrone
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Brain Stroke, Stenting Treatment, Acute Ischemic Stroke
- Interventions
- Mechanical Thrombectomy plus adjunct stenting, Mechanical Thrombectomy
- Procedure · Device
- Lead sponsor
- ProMedica Health System
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Toledo, Ohio
- Conditions
- Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
- Interventions
- Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Sham Subconjunctival Injection, Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%
- Drug · Procedure
- Lead sponsor
- Harrow Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Tyler, Texas
- Conditions
- Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia, Pulmonary; Hypertension
- Interventions
- Fetal Tracheal Occlusion
- Device
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Post-tick Bite Illness, Mast Cell Stabilizer
- Interventions
- Ketotifen, fexofenadine, Cromolyn Sodium
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Coronary Vessel Occlusion
- Interventions
- Indigo Aspiration System
- Device
- Lead sponsor
- Penumbra Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 25
- States / cities
- Los Angeles, California • Orange, California • San Diego, California + 21 more
- Conditions
- Arterial Occlusive Disease, Intermittent Claudication
- Interventions
- Lower extremity Atherectomy and Cryoplasty
- Device
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Knee Pain Chronic, Knee Swelling Pain, Arterial Occlusion
- Interventions
- Embozene Microspheres
- Device
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 40 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- bevacizumab
- Biological
- Lead sponsor
- Outlook Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- Springfield, Illinois • Hagerstown, Maryland • Chambersburg, Pennsylvania
- Conditions
- Macular Edema
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Paducah, Kentucky • Charlotte, North Carolina • Chattanooga, Tennessee + 1 more
- Conditions
- Macular Edema, Cystoid, Retinal Vein Occlusion
- Interventions
- Standard Care, intravitreal triamcinolone injection
- Other · Drug
- Lead sponsor
- The Emmes Company, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 682 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Contraception
- Interventions
- FemBloc
- Device
- Lead sponsor
- Femasys Inc.
- Industry
- Eligibility
- 21 Years to 50 Years · Female only
- Enrollment
- 573 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2031
- U.S. locations
- 12
- States / cities
- Chandler, Arizona • Palo Alto, California • Sacramento, California + 9 more
- Conditions
- Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- AngioVue SD-OCT
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
- Interventions
- Faricimab, Port Delivery System with Ranibizumab
- Drug · Combination Product
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Pasadena, California • Sacramento, California + 15 more